Altimmune, Inc. cotiza a 2.56 USD y tiene una capitalización bursátil de $498M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis,…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.12 | $-0.18 | $-0.27 |
| Estimado | $-0.14 | $-0.12 | $-0.25 | $-0.24 |
| Sorpresa | — | +0.0% | +28.0% | -12.5% |
| Métrica | ALT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -230461.0% | -38.6% | -230422.4% |
| Net Margin | -214861.0% | -33.6% | -214827.4% |
| FCF Margin | -164746.3% | -13.9% | -164732.5% |
| ROE | -39.2% | -40.4% | +1.2% |
| ROA | -31.5% | -32.0% | +0.5% |
| Current Ratio | 18.55 | 2.84 | +15.71 |
| Debt / Equity | 0.15 | 0.28 | -0.13 |